Pancreatic Cancer Research

ResearcherUniversity of TorontoActive in the last 2 years

Natalie G. Coburn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5313-717X; OpenAlex author ID A5058397486, A5113326957. Sources: OpenAlex.

Their work

Papers
20 (first author 5, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2015: 1 paper · 2016: 3 papers · 2017: none · 2018: none · 2019: 5 papers · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 20

  1. Adjuvant Chemoradiotherapy for Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.soc.2025.04.006↗
  2. Factors associated with physical and mental health symptoms in pancreatic adenocarcinoma: a population-based cohort study. Co-author DOI 10.1093/jcag/gwaf040↗
  3. The association between cardiovascular medication use and survival in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1177/17588359261449094↗
  4. Development and Validation of a Survival Prediction Model for Patients With Pancreatic Cancer. Co-author DOI 10.14309/ctg.0000000000000774↗
  5. Treatment Patterns and Outcomes in Pancreatic Cancer: A Comparative Analysis of Ontario and the USA. Co-author DOI 10.1245/s10434-023-14375-6↗
  6. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based … Co-author DOI 10.1016/j.clon.2023.02.008↗
  7. Initial treatment is associated with improved survival and end-of-life outcomes for patients with pancreatic cancer: a cohort study. Co-author DOI 10.1186/s12885-022-10342-8↗
  8. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. Co-author DOI 10.1002/cam4.2705↗
  9. Symptom Burden of Nonresected Pancreatic Adenocarcinoma: An Analysis of 10,753 Patient-Reported Outcome Assessments. Last author DOI 10.1097/mpa.0000000000001629↗
  10. Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. Last author DOI 10.6004/jnccn.2019.7361↗
  11. Impact of Geography on Care Delivery and Survival for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. First author DOI 10.6004/jnccn.2020.7605↗
  12. Population-based study of the prevalence and management of self-reported high pain scores in patients with non-resected pancreatic adenocarcinoma. First author DOI 10.1002/bjs.11330↗
  13. Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarci… Co-author DOI 10.1002/bjs5.50115↗
  14. Symptom trajectories and predictors of severe symptoms in pancreatic adenocarcinoma at the end-of-life: a population based analysis of 2,538 patients. Last author DOI 10.1016/j.hpb.2019.04.016↗
  15. Barriers to Surgical Resection of Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-018-6981-9↗
  16. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. First author DOI 10.1503/cmaj.190211↗
  17. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer. Last author DOI 10.1002/cncr.30148↗
  18. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. Last author DOI 10.1016/j.hpb.2015.12.005↗
  19. Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. Last author DOI 10.3747/co.23.3205↗
  20. A population-based study of the epidemiology of pancreatic cancer: a brief report. First author DOI 10.3747/co.22.2653↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julie I. Hallet · 8 shared papers, 2019–2022 · strength 0.88
  2. Michail N. Mavros · 4 shared papers, 2019–2026 · strength 0.67
  3. Paul Damien James · 3 shared papers, 2022–2026 · strength 0.66
  4. Peter Tanuseputro · 3 shared papers, 2022–2026 · strength 0.66
  5. Rishad Khan · 3 shared papers, 2022–2026 · strength 0.66
  6. Kelvin Chan · 3 shared papers, 2020–2026 · strength 0.61
  7. Michael Jonathon Raphael · 2 shared papers, 2023–2026 · strength 0.53
  8. Sheron Perera · 1 shared paper, 2026 · strength 0.50
  9. Sylvia S. W. Ng · 1 shared paper, 2026 · strength 0.50
  10. Rinku Sutradhar · 2 shared papers, 2025–2026 · strength 0.49
  11. Nicholas Latchana · 2 shared papers, 2019 · strength 0.29
  12. Ahmed Hammad · 3 shared papers, 2019–2020 · strength 0.29
  13. Wei Fang Dai · 2 shared papers, 2020–2023 · strength 0.26
  14. James Biagi · 2 shared papers, 2020–2023 · strength 0.26
  15. Daniel Jonathan Kagedan · 4 shared papers, 2016–2019 · strength 0.25
  16. Nicole Mittmann · 4 shared papers, 2015–2020 · strength 0.23
  17. Ying Liu · 2 shared papers, 2019–2020 · strength 0.21
  18. Stephanie Tung · 2 shared papers, 2019–2020 · strength 0.20
  19. Sten D. Myrehaug · 2 shared papers, 2019 · strength 0.19
  20. Lily V. Saadat · 1 shared paper, 2024 · strength 0.18
  21. Kevin C. Soares · 1 shared paper, 2024 · strength 0.18
  22. T. Peter Kingham · 1 shared paper, 2024 · strength 0.18
  23. Michael Ian D'Angelica · 1 shared paper, 2024 · strength 0.18
  24. Frances Catriona Wright · 1 shared paper, 2024 · strength 0.18
  25. William R. Jarnagin · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.